Article Details

FDA panel rejects Pfizer's tanezumab for osteoarthritis pain over risk-benefit doubts

Retrieved on: 2021-03-25 20:48:45

Tags for this article:

Click the tags to see associated articles and topics

FDA panel rejects Pfizer's tanezumab for osteoarthritis pain over risk-benefit doubts. View article details on hiswai:

Excerpt

A pair of FDA advisory committees has rejected a risk mitigation proposal from Pfizer for its NGF-blocker tanezumab, stating it would fail to ensure the ...

Article found on: www.healio.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up